Nippon Yusen K.K. ADS (NPNYY) Financials Nov 14, 2014, 8:10
Nippon Yusen K.K. ADS (NPNYY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Nippon Yusen K.K. ADS
Fiscal year is April-March. All values JPY millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 1.7T 1.93T 1.81T 1.9T 2.24T
Cost of Goods Sold (COGS) incl. D&A 1.52T 1.62T 1.66T 1.7T 1.99T
COGS excluding D&A 1.42T 1.52T 1.56T 1.61T 1.88T
Depreciation & Amortization Expense 98.02B 100.2B 100.86B 97.52B 107.34B
Depreciation - - - - -
Amortization of Intangibles - - - - 1.39B
Gross Income 176.41B 307.12B 146.71B 192.51B 246.2B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 194.5B 184.78B 170.83B 175.08B 201.2B
Research & Development 1.23B 434M 937M 776M 715M
Other SG&A 193.28B 184.34B 169.89B 174.3B 200.49B
Other Operating Expense 0 0 0 0 0
Unusual Expense 3.66B 17.49B 12.21B 4.32B 28.18B
EBIT after Unusual Expense (3.66B) (17.49B) (12.21B) (4.32B) (28.18B)
Non Operating Income/Expense 26.18B 16.79B 16.6B 33.06B 37.35B
Non-Operating Interest Income 2.65B 1.97B 2.84B 2.13B 2.6B
Equity in Affiliates (Pretax) 2.42B 6.39B 2.16B 1.75B 15.32B
Interest Expense 19.47B 16.83B 16.21B 17.46B 18.99B
Gross Interest Expense 19.47B 16.83B 16.21B 17.46B 18.99B
Interest Capitalized 0 0 0 0 0
Pretax Income (9.97B) 113.19B (30.95B) 32.59B 53.11B
Income Tax 4.78B 31.15B 39.16B 10.86B 15.75B
Income Tax - Current Domestic 12.82B 15.86B 13.94B 11.76B 16.77B
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic (8.04B) 15.29B 25.22B (900M) (1.01B)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates - - - - -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (14.75B) 82.04B (70.11B) 21.74B 37.35B
Minority Interest Expense 2.7B 3.5B 2.71B 2.84B 4.31B
Net Income (17.45B) 78.54B (72.82B) 18.9B 33.05B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (17.45B) 78.54B (72.82B) 18.9B 33.05B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (17.45B) 78.54B (72.82B) 18.9B 33.05B
EPS (Basic) (12.71) 46.27 (42.92) 11.14 19.48
Basic Shares Outstanding 1.37B 1.7B 1.7B 1.7B 1.7B
EPS (Diluted) (12.71) 46.27 (42.92) 11.14 19.48
Diluted Shares Outstanding 1.37B 1.7B 1.7B 1.7B 1.7B
EBITDA 79.93B 222.54B 76.73B 114.96B 152.34B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...
Continue Reading
QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...
Continue Reading
Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....
Continue Reading
LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...
Continue Reading
Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...
Continue Reading